Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II rhNGF eye drops after cataract and refractive surgery
2016-002172-27Phase 2Completed
- Sponsor
- Dompé
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Nerve growth factor in dry eye syndrome (DED), Postoperative ocular surface disease (POSD) and ocular surface disease (OSD) (2 arms), sponsored by Dompé. Primary endpoint: Change from baseline in SANDE scores for severity and frequency at 8 weeks. Started May 2018; status: completed.
02
Drugs
Nerve growth factor
03
Conditions
dry eye syndrome (DED)Postoperative ocular surface disease (POSD)ocular surface disease (OSD)
Beyond the preview
Go deeper on 2016-002172-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002172-27.